The Registry for Prostate Cancer Radiosurgery (RCPR) is a multi-institutional IRB approved prospective observational trial. The goals of the registry include improved quality of care and improved patient access to Stereotactic Body Radiation Therapy (SBRT) for prostate cancer patients. RPCR is a nationwide trial that tracks prostate cancer patient demographics, treatment specifics, outcomes, and payor information.
The registry seeks to eliminate barriers which may limit patient access to SBRT as a viable treatment option and to create a gateway between providers and payers.
Features of the RPCR
- Independently funded and maintained; not directly supported by a manufacturer
- Adaptable for all SBRT platforms
- Available nationally; registered with ClinicalTrials.gov (NCT 01226004)
- Secure, HIPAA compliant
- Data collected and maintained for a minimum of three years
- Data remains the property of the individual participating facility
- Aggregate information analyzed & published annually
Tracked Items
- Patient demographics
- Payor information
- Treatment details
- Baseline and follow up endpoints, including PSA, physical findings, performance status, VAS, IPSS, IEFF-5, and bowel toxicity
Benefits of RPCR participation
- Creates a path for facilities to communicate with Medicare regarding payment for prostate SBRT
- Promotes access to care
- Opportunity for facilities that are not affiliated with academic institutions to make their real-world experiences count
- Potential for self scrutiny by comparison of individual facility results to aggregate results, thereby improving quality of care
- Potential authorship of publications
- Compliments participation in Randomized Clinical Trials
- Encourages collaborative efforts between centers